Angiopoietin-like 3

Angiopoietin-like 3 분자 정보

영어 이름Angiopoietin like 3시판 약물 수1
임상 약물 수14표적 별명Angiopoietin Like 3,Angiopoietin 5,UNQ153/PRO179,Angiopoietin-5,Angiopoietin-like protein 3,ANGPT5,ANG-5,Angiopoietin-Related Protein 3,Angiopoietin-Like 3,FHBL2,ANL3,ANGPTL3
최고 연구 개발 단계Approved
영어 이름Angiopoietin like 3
표적 별명Angiopoietin Like 3,Angiopoietin 5,UNQ153/PRO179,Angiopoietin-5,Angiopoietin-like protein 3,ANGPT5,ANG-5,Angiopoietin-Related Protein 3,Angiopoietin-Like 3,FHBL2,ANL3,ANGPTL3
시판 약물 수1
임상 약물 수14
최고 연구 개발 단계Approved

Angiopoietin-like 3 제품 목록

  • 속성

    Protein (5)

  • 제품 라이브러리

    온라인 (5)

  • Human (4)Mouse (1)

  • 태그

    His Tag (3)His Tag & Avi Tag (1)Fc Tag (1)

  • 마커

    Unconjugated (4)Biotin-labeled (1)

Angiopoietin-like 3분자 배경

Angiopoietin-like protein 3 (ANGPTL3) is also known as Angiopoietin-related protein 3, Angiopoietin-5 (ANGPT5 / ANG-5), is a member of the angiopoietin-like family of secreted factors. ANGPTL3 / ANGPT5 is predominantly expressed in the liver, and has the characteristic structure of angiopoietins, consisting of a signal peptide, N-terminal coiled-coil domain and the C-terminal fibrinogen (FBN)-like domain. The FBN-like domain in angiopoietin-like 3 protein was shown to bind alpha-5/beta-3 integrins, and this binding induced endothelial cell adhesion and migration. This protein may also play a role in the regulation of angiogenesis. Angptl3 also acts as dual inhibitor of lipoprotein lipase (LPL) and endothelial lipase (EL), and increases plasma triglyceride and HDL cholesterol in rodents. ANGPTL3 inhibit endothelial lipase to catalyze HDL-phospholipid and increase HDL-PL levels. Circulating PL-riched HDL particles have high cholesterol efflux abilities.

Angiopoietin-like 3분자 별명

ANGPTL3,ANGPT5,ANG-5,Angiopoietin-5,FHBL2

임상 약물 정보

영어 이름연구 코드연구 개발 단계회사적응증임상 시험
ZodasiranARO-ANG3; ARO-ANG33; VSA-003 (Arrowhead Pharmaceuticals)Phase 3 ClinicalRoche LtdDyslipidemias; Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hyperlipoproteinemia Type II; Hypertriglyceridemia
상세
LNA-043LNA-043Phase 2 ClinicalNovartis Pharma AgKnee Injuries; Osteoarthritis; Osteoarthritis, Knee
상세
VupanorsenISIS-703802; PF-07285557Phase 2 ClinicalIonis Pharmaceuticals IncCardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Homozygous familial hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type I; Hyperlipoproteinemia Type II; Hyperlipoproteinemias; Hypertriglyceridemia; Metabolic Dysfunction-Associated Steatotic Liver Disease
상세
EDP-167EDP-167; EDP167Phase 2 ClinicalEteng Pharmaceutical (Zhuhai) Co LtdDyslipidemias; Homozygous familial hypercholesterolemia
상세
ALN-ANG3ALN-ANG3Phase 2 ClinicalAlnylam Pharmaceuticals IncDiabetic Nephropathies
상세
BW-00112BW-00112; BW00112Phase 2 ClinicalShanghai Argo Biopharmaceutical Co LtdDyslipidemias; Hypertriglyceridemia
상세
SolbinsiranLY-3561774; DCR-CM-1; DCR-CM1Phase 2 ClinicalDicerna Pharmaceuticals IncCardiovascular Diseases; Dyslipidemias; Hyperlipoproteinemias; Hypertriglyceridemia; Lipid Metabolism Disorders; Metabolic Diseases
상세
JS-401JS-401; RP-912Phase 1 ClinicalRisen (Suzhou) Pharma Tech Co LtdHyperlipidemias; Metabolic Diseases
상세
VERVE-201VERVE-201Phase 1 ClinicalBroad Institute, Harvard UniversityAtherosclerosis; Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hypertriglyceridemia
상세
SYH-2070SYH2070; SYH-2070Phase 1 ClinicalCspc Heibei Zhongrun Pharmaceutiacl Co LtdHyperlipidemia, Familial Combined; Hyperlipidemias; Hypertriglyceridemia
상세
NN-6491NN6491; NN-6491Phase 1 ClinicalNovo Nordisk A/SCardiovascular Diseases
상세
NNC0491-6075NNC0491-6075; NNC04916075Phase 1 ClinicalNovo Nordisk A/SDyslipidemias
상세
AZD-1705AZD1705; AZD-1705Phase 1 ClinicalAstrazeneca Plc, Parexel International CorpCardiovascular Diseases
상세
CTX-310CTX-310; CTX310Phase 1 ClinicalCrispr Therapeutics AgCardiovascular Diseases; Dyslipidemias; Heterozygous familial hypercholesterolemia; Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hyperlipidemias; Hypertriglyceridemia; Lipid Metabolism Disorders; Metabolic Diseases; Sitosterolemia
상세

시판 약물 정보

영어 이름연구 코드연구 개발 단계회사가장 빠른 브랜드 이름가장 빠른 승인 국가가장 빠른 적응증가장 빠른 승인 회사가장 빠른 승인 날짜적응증임상 시험
EvinacumabREGN-1500ApprovedRegeneron Pharmaceuticals IncEvkeezaUnited StatesHypercholesterolemia; Homozygous familial hypercholesterolemiaRegeneron Pharmaceuticals Inc2021-02-11Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hypertriglyceridemia; Metabolic Diseases
상세
  • 분자 정보
  • 제품 목록
  • 시판 약물 정보
  • 임상 약물 정보
문의하기

전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521

주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호